Nature Communications (Aug 2022)
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity
- Lino Möhrmann,
- Maximilian Werner,
- Małgorzata Oleś,
- Andreas Mock,
- Sebastian Uhrig,
- Arne Jahn,
- Simon Kreutzfeldt,
- Martina Fröhlich,
- Barbara Hutter,
- Nagarajan Paramasivam,
- Daniela Richter,
- Katja Beck,
- Ulrike Winter,
- Katrin Pfütze,
- Christoph E. Heilig,
- Veronica Teleanu,
- Daniel B. Lipka,
- Marc Zapatka,
- Dorothea Hanf,
- Catrin List,
- Michael Allgäuer,
- Roland Penzel,
- Gina Rüter,
- Ivan Jelas,
- Rainer Hamacher,
- Johanna Falkenhorst,
- Sebastian Wagner,
- Christian H. Brandts,
- Melanie Boerries,
- Anna L. Illert,
- Klaus H. Metzeler,
- C. Benedikt Westphalen,
- Alexander Desuki,
- Thomas Kindler,
- Gunnar Folprecht,
- Wilko Weichert,
- Benedikt Brors,
- Albrecht Stenzinger,
- Evelin Schröck,
- Daniel Hübschmann,
- Peter Horak,
- Christoph Heining,
- Stefan Fröhling,
- Hanno Glimm
Affiliations
- Lino Möhrmann
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- Maximilian Werner
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- Małgorzata Oleś
- Computational Oncology Group, NCT Heidelberg and DKFZ
- Andreas Mock
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Sebastian Uhrig
- Computational Oncology Group, NCT Heidelberg and DKFZ
- Arne Jahn
- Center for Personalized Oncology, NCT Dresden and University Hospital Carl Gustav Carus, Faculty of Medicine and Technische Universität Dresden
- Simon Kreutzfeldt
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Martina Fröhlich
- Computational Oncology Group, NCT Heidelberg and DKFZ
- Barbara Hutter
- Computational Oncology Group, NCT Heidelberg and DKFZ
- Nagarajan Paramasivam
- Computational Oncology Group, NCT Heidelberg and DKFZ
- Daniela Richter
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- Katja Beck
- Molecular Precision Oncology Program, NCT Heidelberg
- Ulrike Winter
- Molecular Precision Oncology Program, NCT Heidelberg
- Katrin Pfütze
- Molecular Precision Oncology Program, NCT Heidelberg
- Christoph E. Heilig
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Veronica Teleanu
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Daniel B. Lipka
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Marc Zapatka
- Division of Molecular Genetics, DKFZ
- Dorothea Hanf
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- Catrin List
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- Michael Allgäuer
- Institute of Pathology, University Hospital Heidelberg
- Roland Penzel
- Institute of Pathology, University Hospital Heidelberg
- Gina Rüter
- Charité Comprehensive Cancer Center, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin
- Ivan Jelas
- Charité Comprehensive Cancer Center, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin
- Rainer Hamacher
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen
- Johanna Falkenhorst
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen
- Sebastian Wagner
- Department of Medicine 2, Hematology/Oncology, Goethe University
- Christian H. Brandts
- Department of Medicine 2, Hematology/Oncology, Goethe University
- Melanie Boerries
- Institute of Medical Bioinformatics and Systems Medicine, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg
- Anna L. Illert
- DKTK
- Klaus H. Metzeler
- Department of Internal Medicine III, University Hospital, LMU Munich and Comprehensive Cancer Center
- C. Benedikt Westphalen
- Department of Internal Medicine III, University Hospital, LMU Munich and Comprehensive Cancer Center
- Alexander Desuki
- University Cancer Center Mainz, University Medical Center Mainz
- Thomas Kindler
- University Cancer Center Mainz, University Medical Center Mainz
- Gunnar Folprecht
- Center for Personalized Oncology, NCT Dresden and University Hospital Carl Gustav Carus, Faculty of Medicine and Technische Universität Dresden
- Wilko Weichert
- Institute of Pathology, Technical University Munich
- Benedikt Brors
- Division of Applied Bioinformatics, NCT Heidelberg and DKFZ
- Albrecht Stenzinger
- Institute of Pathology, University Hospital Heidelberg
- Evelin Schröck
- Center for Personalized Oncology, NCT Dresden and University Hospital Carl Gustav Carus, Faculty of Medicine and Technische Universität Dresden
- Daniel Hübschmann
- Computational Oncology Group, NCT Heidelberg and DKFZ
- Peter Horak
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Christoph Heining
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- Stefan Fröhling
- Department of Translational Medical Oncology, NCT Heidelberg and DKFZ
- Hanno Glimm
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
- DOI
- https://doi.org/10.1038/s41467-022-31866-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
The identification of molecular biomarkers in cancer of unknown primary site (CUP) cases may enable the improvement of prognosis in these patients. Here, the authors integrate whole genome/exome, transcriptome and methylome data in 70 CUP patients, recommend therapies based on their analysis and report clinical outcome data.
